Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ESSA Pharma's current ratio for the quarter that ended in Jun. 2025 was 69.06.
ESSA Pharma has a current ratio of 69.06. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for ESSA Pharma's Current Ratio or its related term are showing as below:
EPIX's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.88 * Ranked among companies with meaningful Current Ratio only.
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
ESSA Pharma Current Ratio Related Terms
ESSA Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for ESSA Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPIX vs SLXN, NLSP, PTNT: Current Ratio Comparison
For the Biotechnology subindustry, ESSA Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ESSA Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ESSA Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where ESSA Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESSA Pharma (EPIX) has a Current Ratio of 69.06 as of Jun. 2025.
Is ESSA Pharma's Current Ratio too high?
ESSA Pharma's current Current Ratio is 69.06. The Biotechnology industry median Current Ratio is 3.88. ESSA Pharma's value of 69.06 is 1679.9% above this industry median. Overall, ESSA Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does ESSA Pharma's Current Ratio compare to SLXN and NLSP?
ESSA Pharma's Current Ratio of 69.06 can be compared against companies in the Biotechnology industry. The industry median Current Ratio is 3.88. ESSA Pharma's value of 69.06 is 1679.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ESSA Pharma's current Current Ratio of 69.06 is 1679.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ESSA Pharma's current Current Ratio is 69.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ESSA Pharma stock overvalued right now?
ESSA Pharma (EPIX) has a current Current Ratio of 69.06. The current Current Ratio is 69.06 and 1679.9% above the Biotechnology industry median of 3.88. ESSA Pharma's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ESSA Pharma (EPIX), the current Current Ratio is 69.06 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
22GF Score
Get the complete analysis for EPIX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EPIX has been successfully added to your 
